ChiCTR2200062868: CDK4 Inhibitor Dalpiciclib in Patients with Advanced CDK4-Amplifified Well-Differentiated or Dedifferentiated Liposarcoma: a prospective, open-label, single-arm and multi-center clinical study |
|
|
| Not yet recruiting | 2 | 40 | | Dalpiciclib | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, partly self-funded, partly provied by jiangsu hengrui pharmaceutical co. | Well-Differentiated or Dedifferentiated Liposarcoma | | | | |
